-
A total of 3,372 people were surveyed from large cities in China, of whom 1,572 were males and 1,800 were females (including 78 pregnant women), accounting for 46.6% and 53.4%, respectively. Among them, detailed population samples were mainly divided into five subgroups. The age, sex grouping of the participants, and hsCRP concentration (mg/L) for population in large cities were shown in Table 1. The percentile distribution of hsCRP for population in large cities (mg/L) is shown inTable 2.
Table 1. hsCRP concentration for population in large cities (mg/L)
Age (years) Male Female Total ${{\rm{\bar {\text{X}}}}_{\text{G}}}$ 95% CI ${{\rm{\bar {\text{X}}}}_{\text{G}}}$ 95% CI ${{\rm{\bar {\text{X}}}}_{\text{G}}}$ 95% CI Total 0.68 0.64–0.72 0.65 0.62–0.69 0.67 0.64–0.70 6–11 0.34 0.30–0.40 0.34 0.29–0.40 0.34 0.31–0.38 12–17 0.37 0.32–0.43 0.30 0.26–0.34 0.33 0.30–0.37 18–44 0.74 0.66–0.83 0.54 0.48–0.59 0.62 0.57–0.67 45–59 0.91 0.81–1.02 0.94 0.85–1.06 0.93 0.86–1.00 ≥ 60 1.05 0.93–1.18 1.14 1.02–1.26 1.09 1.01–1.18 Pregnant 1.42 1.16–1.73 1.42 1.16–1.73 Table 2. Percentile distribution of hsCRP for population in the large cities (mg/L)
Age (years) n P2.5 P5 P10 P25 P50 P75 P90 P95 P97.5 Total Subtotal 3,372 0.10 0.13 0.16 0.27 0.59 1.43 3.35 5.48 9.32 6–11 489 0.08 0.09 0.11 0.16 0.26 0.58 1.92 4.00 7.16 12–17 463 0.08 0.10 0.12 0.16 0.25 0.51 1.56 3.22 6.36 18–44 774 0.11 0.15 0.19 0.28 0.52 1.20 2.65 4.70 6.42 45–59 779 0.15 0.19 0.26 0.42 0.82 1.72 3.92 6.37 16.42 ≥ 60 789 0.17 0.22 0.29 0.49 0.98 2.22 4.66 8.50 13.79 Pregnant 78 0.18 0.29 0.41 0.74 1.50 2.59 4.22 6.66 7.86 Male 6–11 241 0.08 0.09 0.12 0.16 0.26 0.62 1.90 3.59 6.54 12–17 227 0.07 0.11 0.13 0.17 0.28 0.61 1.96 4.20 6.53 18–44 349 0.15 0.18 0.21 0.32 0.65 1.56 3.17 5.05 6.14 45–59 364 0.16 0.19 0.28 0.41 0.81 1.84 3.92 5.60 12.10 ≥ 60 391 0.18 0.21 0.27 0.43 0.93 2.08 4.76 9.00 19.18 Subtotall 1,572 0.10 0.14 0.17 0.28 0.58 1.44 3.56 5.45 10.99 Female 6–11 248 0.06 0.09 0.11 0.15 0.26 0.57 2.06 4.35 7.67 12–17 236 0.07 0.10 0.12 0.15 0.24 0.43 1.25 2.35 4.93 18–44 425 0.11 0.13 0.17 0.25 0.44 0.98 2.07 4.17 6.74 45–59 415 0.14 0.19 0.25 0.43 0.85 1.70 3.97 8.13 22.31 ≥ 60 398 0.16 0.23 0.32 0.59 1.08 2.26 4.48 7.28 10.39 Subtotal 1,800 0.10 0.12 0.15 0.26 0.59 1.41 3.22 5.68 9.00 Pregnant 78 0.18 0.29 0.41 0.74 1.50 2.59 4.22 6.66 7.86 -
The average concentration of hsCRP in large urban residents was 0.67 mg/L, with 0.68 mg/L for men and 0.65 mg/L for women. The difference in hsCRP among the different age groups was statistically significant (P < 0.05), and the details are shown in Table 1. No significant difference in hsCRP levels was found between males and females aged ≥ 60 years and aged 45–59 years, but the two groups had significantly higher hsCRP levels than the other age subgroups (P < 0.05).
At the same time, the hsCRP levels in the 18–44 year-old group was significantly higher than that in the 6–11 and 12–17 year-old groups (P < 0.01). The highest hsCRP concentration was found in pregnant women in large cities. It was not significantly different from that in the ≥ 60-year-old group but significantly higher than those in the four other age groups ( P < 0.05). Meanwhile, the levels in the 45–59-year-old group were significantly higher than those in the 6–11, 12–17, and 18–44 year-old groups ( P < 0.01). The levels in the 18–44 year-old group were significantly higher than those in the 6–11 and 12–17 year-old groups ( P < 0.01). No significant difference in hsCRP was found between the 6–11 and 12–17 year-old groups.
The effect of different ages and genders on hsCRP in the residents of large cities is shown in Figure 1. The hsCRP increased with increasing age for the females and males. The concentration of hsCRP was substantially higher in the women aged > 55 years old than in the younger females. As shown in Figure 2, the distribution of hsCRP frequency in large cities was non-normally distributed.
The box plots of hsCRP distribution for residents of different ages and genders are shown in Figure 3. The highest median hsCRP was found in pregnant women.
Figure 3. Box plots presenting the distribution of hsCRP for population by age and sex in large cities.
The distribution of percentiles of hsCRP levels in residents of urban areas is shown in Table 2.
doi: 10.3967/bes2020.054
Distribution of High-sensitivity C-reactive Protein Status in an Urban Population in China
-
Abstract:
Objectives To evaluate the distribution by age and sex of serum high-sensitivity C-reactive protein (hsCRP) in an urban Chinese population and to provide a profile prediction for the risk of bacterial infection, inflammatory diseases, or tissue damages in the body. Methods Serum hsCRP was determined using the Roche Tina-quant immuno-turbidimetric assay on a Hitachi 7600–010 automatic biochemical analyzer (Roche Diagnostics) in 1,572 males and 1,800 females, including 78 pregnant women, who were derived from the National Health and Nutrition Survey in 2010–2012. Results The average hsCRP concentration in urban China was 0.68 mg/L for males and 0.65 mg/L for females. Significant differences in hsCRP were found among different age groups (P < 0.05). Monitoring results showed no significant differences among the 6–11, 45–59, and ≥ 60-year-old groups in the comparison of hsCRP between males and females in large cities. However, hsCRP concentration was significantly higher in men aged 12–17 and 18–44 years than in women. Conclusion The distribution of the hsCRP status of residents in large cities in China was influenced by age and gender, and the hsCRP levels of both sexes increased gradually with age. In addition, hsCRP concentration was higher in healthy pregnant women than in non-pregnant women. Basing on our results, we recommend that this parameter be included in future national and international screening for early detection of various illnesses. -
Key words:
- High-sensitivity C-reactive protein /
- Urban population /
- Inflammation /
- Distribution
注释: -
Table 1. hsCRP concentration for population in large cities (mg/L)
Age (years) Male Female Total ${{\rm{\bar {\text{X}}}}_{\text{G}}}$ 95% CI ${{\rm{\bar {\text{X}}}}_{\text{G}}}$ 95% CI ${{\rm{\bar {\text{X}}}}_{\text{G}}}$ 95% CI Total 0.68 0.64–0.72 0.65 0.62–0.69 0.67 0.64–0.70 6–11 0.34 0.30–0.40 0.34 0.29–0.40 0.34 0.31–0.38 12–17 0.37 0.32–0.43 0.30 0.26–0.34 0.33 0.30–0.37 18–44 0.74 0.66–0.83 0.54 0.48–0.59 0.62 0.57–0.67 45–59 0.91 0.81–1.02 0.94 0.85–1.06 0.93 0.86–1.00 ≥ 60 1.05 0.93–1.18 1.14 1.02–1.26 1.09 1.01–1.18 Pregnant 1.42 1.16–1.73 1.42 1.16–1.73 Table 2. Percentile distribution of hsCRP for population in the large cities (mg/L)
Age (years) n P2.5 P5 P10 P25 P50 P75 P90 P95 P97.5 Total Subtotal 3,372 0.10 0.13 0.16 0.27 0.59 1.43 3.35 5.48 9.32 6–11 489 0.08 0.09 0.11 0.16 0.26 0.58 1.92 4.00 7.16 12–17 463 0.08 0.10 0.12 0.16 0.25 0.51 1.56 3.22 6.36 18–44 774 0.11 0.15 0.19 0.28 0.52 1.20 2.65 4.70 6.42 45–59 779 0.15 0.19 0.26 0.42 0.82 1.72 3.92 6.37 16.42 ≥ 60 789 0.17 0.22 0.29 0.49 0.98 2.22 4.66 8.50 13.79 Pregnant 78 0.18 0.29 0.41 0.74 1.50 2.59 4.22 6.66 7.86 Male 6–11 241 0.08 0.09 0.12 0.16 0.26 0.62 1.90 3.59 6.54 12–17 227 0.07 0.11 0.13 0.17 0.28 0.61 1.96 4.20 6.53 18–44 349 0.15 0.18 0.21 0.32 0.65 1.56 3.17 5.05 6.14 45–59 364 0.16 0.19 0.28 0.41 0.81 1.84 3.92 5.60 12.10 ≥ 60 391 0.18 0.21 0.27 0.43 0.93 2.08 4.76 9.00 19.18 Subtotall 1,572 0.10 0.14 0.17 0.28 0.58 1.44 3.56 5.45 10.99 Female 6–11 248 0.06 0.09 0.11 0.15 0.26 0.57 2.06 4.35 7.67 12–17 236 0.07 0.10 0.12 0.15 0.24 0.43 1.25 2.35 4.93 18–44 425 0.11 0.13 0.17 0.25 0.44 0.98 2.07 4.17 6.74 45–59 415 0.14 0.19 0.25 0.43 0.85 1.70 3.97 8.13 22.31 ≥ 60 398 0.16 0.23 0.32 0.59 1.08 2.26 4.48 7.28 10.39 Subtotal 1,800 0.10 0.12 0.15 0.26 0.59 1.41 3.22 5.68 9.00 Pregnant 78 0.18 0.29 0.41 0.74 1.50 2.59 4.22 6.66 7.86 -
[1] Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci, 1982; 389, 406−8. doi: 10.1111/j.1749-6632.1982.tb22153.x [2] Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med, 2005; 2, 29−36. doi: 10.1038/ncpcardio0074 [3] Waliza A, Shymasree G. C-reactive protein and the biology of disease. Immunol Res, 2013; 56, 131−42. doi: 10.1007/s12026-013-8384-0 [4] Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med, 1930; 52, 561−71. doi: 10.1084/jem.52.4.561 [5] Wang ZW, Wang X, Chen Z, et al. Distribution of high-sensitivity C-reactive protein and its relationship with other cardiovascular risk factors in the middle-age Chinese population. Int J Environ Res Public Health, 2016; 13, 872. doi: 10.3390/ijerph13090872 [6] Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest, 2003; 111, 1805−12. doi: 10.1172/JCI200318921 [7] Salazar J, Martinez MS, Chavez M, et al. C-reactive protein: clinical and epidemiological perspectives. Cardiol Res Pract, 2014; 56, 131−42. [8] Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res, 2013; 48, 155−70. [9] Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med, 1999; 17, 1019−25. doi: 10.1016/S0736-4679(99)00135-3 [10] Das T, Sen A, Kempf T, et al. Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J, 2003; 373, 345−55. doi: 10.1042/bj20021701 [11] Yi P. Comparison of the results of two methods in detecting CRP and hsCRP. Acta Medicinae Sinica, 2015; 28, 95−8. [12] Yu H, Rifai N. High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin Biochem, 2000; 8, 601−10. [13] Allin KH, Nordestgaard BG. Elevated C-reactive protein in diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci, 2011; 26, 209−15. [14] Yang LF, Chen AH, Gu CB, et al. Clinical value of serum highsensitive C-reactive protein detection in patients with unstable angina pectoris. Appl J General Pract, 2007; 5, 798−9. (In Chinese) [15] Wu ZT, Li L, Ma ZZ, et al. The changes and the clinical significance of CRP level in serum in CHF. Chinese Journal of General Practice, 2010; 18, 1403−4. (In Chinese) [16] Li XJ, Wang YN, Fan X, et al. High-sensitivety c-reactive protein and its clinical significance in cardiovascular diseases. Adv Cardiovase Dis, 2007; 28, 92−6. [17] Zhang XH, Li GT, Zhang ZL. Clinical Significances of C-reactive protein and hypersensitive C-reactive protein. Chin J Aller Clini Immunol, 2011; 5, 74−9. (In Chinese) [18] Hung J, Knuiman MW, Divitini ML, et al. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am J Cardiol, 2008; 101, 193−8. doi: 10.1016/j.amjcard.2007.07.061 [19] McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care, 2009; 12, 223−6. doi: 10.1097/MCO.0b013e32832a7902 [20] Khera A, McGuire DK, Murphy SA, et al. Race and gender different in C-reactive protein levels. J Am Coll Cardiol, 2005; 46, 464−9. doi: 10.1016/j.jacc.2005.04.051 [21] Lin GM, Liu K, Colangel LA, et al. Low-density lipoprotein cholesterol concentrations and association of high-sensitivity C-reactive protein concentration with incident coronary heart disease in the multi-ethnic study of atheroscerosis. Am J Epidemiol, 2016; 183, 46−52. doi: 10.1093/aje/kwv144 [22] Zhao YF, Wang R, Ma XQ, et al. Distribution of C-reactive protein and its association with cardiovascular risk factors in a population-based sample of Chinese. Dis Markers, 2010; 28, 333−42. doi: 10.1155/2010/270126 [23] Sung KC, Ryu S, Chang Y, et al. C-reactive protein and risk of cardiovascular and all-cause mortality in 268803 East Asians. Eur Heart J, 2014; 35, 1809−16. doi: 10.1093/eurheartj/ehu059 [24] Wang LJ, Huang J, Li H, et al. Distribution of iron status among urban Chinese women. Asia Pac J Clin Nutr, 2016; 25, 150−7. [25] National Center for Health Statistics. National Health and Nutrition Examination Survey 2005-2006. Documentation, codebook, and frequencies. Laboratory component. 2008/4 [cited 2014/2]; http://www.cdc.gov/nchs/nhanes/nhanes/2005-2006/FERTIN_D.htm. [26] Sisman AR, Kume T, Tas G, et al. Comparison and evaluation of two C-reactive protein assays based on particle-enhanced immunoturbidimetry. J Clin Lab Anal, 2007; 21, 71−6. doi: 10.1002/jcla.20141 [27] Tang XF, Lin TS, Zhao ZH, et al. Distribution and analysis of trace CRP in blood of 492 healthy people. Shanghai J of Med Lab Sci, 2003; 18, 314−6. (In Chinese) [28] Dong Q, Yang D, Ye H, et al. Distributions of C-reactive protein and association with lipid in 579 healthy volunteers. Clin J Hemor, 2006; 26, 444−6. (In Chinese) [29] Yuan BJ, Zhang HF, Zou JM, et al. Distribution of C-reactive protein in healthy adult serum. Chin J Clin Lab Sci, 2005; 23, 236−7. (In Chinese) [30] Song HW. Expression of serum high sensitive C reactive protein in high LDL-C patient. Chin J Med Writ, 2004; 11, 561−2. (In Chinese) [31] Choi EY, Park EH, Cheong YS, et al. Association of C-reactive protein with the metabolic risk factors among young and middle-aged Koreans. Metabolism, 2006; 55, 415−21. doi: 10.1016/j.metabol.2005.11.002 [32] Ford ES, Giles WH, Mokdad AH, et al. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem, 2004; 50, 574−81. doi: 10.1373/clinchem.2003.027359 [33] Hwang HS, Kwon JY, Kim MA, et al. Maternal serum highly sensitive C-reactive protein in normal pregnancy and preeclampsia. Int J Gynaecol Obstet, 2007; 98, 105−9. doi: 10.1016/j.ijgo.2007.03.050 [34] Belo L, Santos-Silva A, Rocha S, et al. Pereira-Leite L. Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol, 2005; 123, 46−51. doi: 10.1016/j.ejogrb.2005.02.022 [35] Wang LR. Relationship between serum C-reactive protein level and gestational diabetes mellitus. J Clin Pathol Res, 2016; 36, 924−8. [36] Tian M, Wu LF. Analysis on the clinical characteristics of pregnant women with gestational diabetes mellitus combined with hypertensive disorder complicating pregnancy and serum levels of C-reactive protein interleukin-6 and tumor necrosis factor-α. Maternal and Child Health Care of China, 2012; 27, 1318−21. (In Chinese) [37] de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and intervenetions. Clin Chim Acta, 2002; 317, 1−15. doi: 10.1016/S0009-8981(01)00797-5 [38] Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American college of on practice guidelins. J Am Coll Cardiol, 2010; 56, e50−e103. doi: 10.1016/j.jacc.2010.09.001